Jim Simons
ATHE

Jim Simons’s Alterity Therapeutics ATHE Stock Holding History

Jim Simons’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-23,790
Closed -$309K – 3460
2021
Q2 		$309K Buy
23,790
+1,321
+6% +$17.9K ﹤0.01% 3138
2021
Q1 		$324K Sell
22,469
-9,681
-30% -$163K ﹤0.01% 3040
2020
Q4 		$431K Buy
32,150
+15,928
+98% +$251K ﹤0.01% 2885
2020
Q3 		$328K Buy
+16,222
New +$330K ﹤0.01% 2961
2018
Q4 		– Sell
-2,522
Closed -$51K – 3368
2018
Q3 		$51K Sell
2,522
-220
-8% -$4.58K ﹤0.01% 3281
2018
Q2 		$52K Buy
+2,742
New +$54.4K ﹤0.01% 3187
2017
Q1 		– Sell
-1,630
Closed -$27K – 3216
2016
Q4 		$27K Sell
1,630
-292
-15% -$7.81K ﹤0.01% 3195
2016
Q3 		$87K Buy
+1,922
New +$95.8K ﹤0.01% 3193
2013
Q4 		– Sell
-2,720
Closed -$671K – 2832
2013
Q3 		$671K Buy
+2,720
New +$624K ﹤0.01% 2191

Other funds holding ATHE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
PCA
Providence Capital Advisors Charlotte, North Carolina $660M AUM 17.81% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
OIA
Optimum Investment Advisors Chicago, Illinois $252M AUM 26.44% 1-Year Est. Return

Jim Simons's ATHE Position: Q3 2021 in Review

Jim Simons sold out of Alterity Therapeutics (ATHE) in Q3 2021, closing a stake of 23,790 shares — an estimated $309K sold.

Jim Simons first reported a position in ATHE in Q3 2013 and held it in 9 quarters. The position peaked at $671K in Q3 2013. 14 funds tracked by Wall St. Rank hold ATHE as of Q3 2021.

  • Jim Simons reported no remaining Alterity Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Jim Simons sold 23,790 Alterity Therapeutics shares in Q3 2021, an estimated $309K.
  • Jim Simons first reported a position in Alterity Therapeutics in Q3 2013 and held it in 9 quarters.
  • Jim Simons's Alterity Therapeutics position peaked at $671K in Q3 2013.
  • 14 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q3 2021.

Based on Renaissance Technologies's 13F filing for Q3 2021, filed 12 Nov 2021.